1. Home
  2. BFST vs CTMX Comparison

BFST vs CTMX Comparison

Compare BFST & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Business First Bancshares Inc.

BFST

Business First Bancshares Inc.

HOLD

Current Price

$27.85

Market Cap

877.1M

Sector

Finance

ML Signal

HOLD

Logo CytomX Therapeutics Inc.

CTMX

CytomX Therapeutics Inc.

HOLD

Current Price

$3.73

Market Cap

977.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BFST
CTMX
Founded
2006
2008
Country
United States
United States
Employees
842
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
877.1M
977.1M
IPO Year
2014
2015

Fundamental Metrics

Financial Performance
Metric
BFST
CTMX
Price
$27.85
$3.73
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
10
Target Price
$32.75
$12.10
AVG Volume (30 Days)
135.1K
2.9M
Earning Date
04-27-2026
05-08-2026
Dividend Yield
2.23%
N/A
EPS Growth
23.45
N/A
EPS
0.68
N/A
Revenue
$10,704,000.00
$76,201,000.00
Revenue This Year
$22.71
N/A
Revenue Next Year
$5.02
$7.61
P/E Ratio
$39.85
$22.58
Revenue Growth
1.20
N/A
52 Week Low
$22.56
$1.72
52 Week High
$30.32
$8.21

Technical Indicators

Market Signals
Indicator
BFST
CTMX
Relative Strength Index (RSI) 54.44 38.55
Support Level $26.78 $3.39
Resistance Level $27.89 $3.91
Average True Range (ATR) 0.53 0.21
MACD 0.01 -0.02
Stochastic Oscillator 95.35 32.46

Price Performance

Historical Comparison
BFST
CTMX

About BFST Business First Bancshares Inc.

Business First Bancshares Inc is a bank holding company. The company's services include personal and commercial banking, treasury management, and wealth solutions. It provides a range of financial services to small-to-midsized businesses and professionals. The company generates the majority of its revenues from interest income on loans, customer service and loan fees, and interest income from securities.

About CTMX CytomX Therapeutics Inc.

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

Share on Social Networks: